Investigating a new imaging technique for measuring glycolysis in glioblastoma tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to validate a novel combined MRI and PET imaging technique as a biomarker for glycolysis in brain tumors, specifically glioblastoma multiforme. Patients scheduled for tumor resection will undergo FDG-PET scans and investigational MR imaging sequences to calculate a 'glycolytic index'. The study will correlate imaging measurements with tissue pH, RNA expression, protein expression, and bioenergetics of key glycolytic enzymes obtained from biopsied tumor tissue. The goal is to determine if metabolic differences identified through imaging can help detect infiltrating non-enhancing tumor cells.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18
* Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery

Exclusion Criteria:

* Patients who cannot obtain an MRI or FDG PET scan with contrast
* Those with ferromagnetic implanted devices that might produce a safety hazard (e.g. infusion pumps, pace makers, aneurysm clips, etc.) will be excluded from the study along with subjects with severe claustrophobia or who have severely compromised renal function (GFR \< 30).

Where it's running

• University of California at Los Angeles
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Benjamin Ellingson, PhD — University of California at Los Angeles
• Study coordinator: Raksha Nagaraj
• Email: RNagaraj@mednet.ucla.edu
• Phone: 310-794-8995

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Boosting outcomes after osimertinib plus chemotherapy by adding surgery or focal radiation to the primary lung tumor

  This trial will test whether giving surgery or focused radiation to the main lung tumor helps people with EGFR-mutant advanced non-small cell lung cancer who have disease controlled after first-line osimertinib plus chemotherapy stay progression-free longer.

  Recruiting Phase 2 Pusan National University Hospital · Busan · NCT07073365

• Adding ruxolitinib to standard radiation and temozolomide for newly diagnosed glioblastoma

  This trial will try whether adding the oral drug ruxolitinib to standard radiation and temozolomide helps adults newly diagnosed with glioblastoma.

  Recruiting at 2 sites Phase 2 Baptist Health South Florida · Miami, Florida and 1 other locations · NCT06991101

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Using low-intensity magnetic therapy for newly diagnosed glioblastoma patients

  This study is testing whether a low-intensity magnetic therapy device can safely help people who have just been diagnosed with glioblastoma.

  Recruiting at 6 sites BioTex, Inc. · Stuttgart, Baden-Wurttemberg and 5 other locations · NCT06533163

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.